HRS-2189 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Oncology • Solid Tumor

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=300 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Fudan University

Metastases • New P2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Hengrui Medicine’s innovative drug HRS-2189 tablets for combination therapy of advanced solid tumors approved for clinical trials [Google translation] (Jiangsu Hengrui Press Release) - "Recently, Hengrui Medicine...received the 'Notice of Approval for Drug Clinical Trial' approved and issued by the National Medical Products Administration, approving the company to conduct an open, multicenter Phase IB/II clinical study on the safety, tolerability, pharmacokinetics and preliminary efficacy of HRS-2189 combined with fulvestrant with or without HRS-6209, or with HRS-6209 and HRS-8080, or with HRS-6209 and HRS-1358, or with abiraterone acetate tablets (II) and prednisone tablets, or with HRS-5041, or with adebelimumab with or without SHR - 8068 with or without chemotherapy, or with adebelimumab and bevacizumab in subjects with advanced unresectable or metastatic solid tumors."

Trial status • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=300 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Breast Cancer • Oncology • Solid Tumor

Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

Metastases • New P1 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2